Selective lymph node removal for small non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and efficacy of a selective lymph node dissection strategy for patients with invasive non-small cell lung cancer (NSCLC) that have a central tumor ratio (CTR) between 0.5 and 1 and a diameter of 2 cm or less. The approach aims to minimize trauma by avoiding unnecessary lymph node removal based on tumor location and characteristics. The study builds on previous findings that certain tumor types and locations are less likely to metastasize, allowing for a more tailored surgical approach. By validating this selective strategy, the study seeks to improve patient outcomes while reducing surgical complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
* Age 18-80 years at time of signing informed consent (including threshold);
* ECOG score 0 or 1;
* No previous surgery for lung cancer;
* Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
* Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;
* The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;
* Patients with clinical stage T1N0M0 surgically resectable;
* Primary treatment without radiotherapy or chemotherapy.

Exclusion Criteria:

* T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm;
* Inability to perform complete surgical resection;
* cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
* Previous surgery for lung cancer;
* Patients who have received radiotherapy or chemotherapy for non-primary treatment.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Haiquan Chen — Fudan University
• Study coordinator: Penghao Deng
• Email: 18301050196@fudan.edu.cn
• Phone: +86-13278979834

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Understanding what patients want from NSCLC treatment monitoring

  Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.

  Recruiting European Institute of Oncology · Milan, mI · NCT07909343

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC

  This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07841249

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• NUT Project: Nutritional Support in Thoracic Cancer

  We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.

  Recruiting Casa di Cura Dott. Pederzoli · Peschiera del Garda, Verona · NCT07817329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.